| 摘要 |
FIELD: chemistry. ^ SUBSTANCE: in formula (I) X1 is O; R1 is hydrogen; R2 is hydrogen or C1-7-alkyl, R3 is hydrogen or C1-7-alkyl; R4 and R8 are independently selected from a group consisting of hydrogen, C1-7-alkyl and halogen; R5, R6 and R7 are independently selected from a group consisting of hydrogen and halogen; and one of R5, R6 and R7 is a group, where X2 is selected from a group consisting of S, O, NR9 and (CH2)pNR9CO; R9 is selected from a group consisting of hydrogen and C1-7-alkyl; R10 is C1-7-alkyl; R11 is selected from a group consisting of hydrogen and C1-7-alkyl; or R10 and R11 together with the carbon atom with which they are bonded form a C3-6-cycloalkyl ring; o equals 0, 1 or 2; n equals 0, 1, 2 or 3; p equals 0 or 1; and the sum of m, n and o assumes values from 1 to 5; R12 is phenyl optionally substituted with fluoro-C1-7-alkoxy, halogen, C1-7-alkoxy, fluro-C1-7-alkyl; or R12 is pyridine or pyrimidine substituted with fluoro-C1-7-alkyl; and their pharmaceutically acceptable salts and/or esters. Present invention also relates to pharmaceutical compositions which have agonistic effect on PPAR and/or PPAR containing such compounds. ^ EFFECT: new compounds have useful biological properties. ^ 20 cl, 36 ex |
